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Abstract
Cytoskeletal structure is continually remodeled to accommodate normal cell growth and to
respond to pathophysiological cues. As a consequence, several cytoskeleton-interacting proteins
become involved in a variety of cellular processes such as cell growth and division, cell
movement, vesicle transportation, cellular organelle location and function, localization and
distribution of membrane receptors, and cell-cell communication. Molecular chaperones and
immunophilins are counted among the most important proteins that interact closely with the
cytoskeleton network, in particular with microtubules and microtubule-associated factors. In
several situations, heat-shock proteins and immunophilins work together as a functionally active
heterocomplex, although both types of proteins also show independent actions. In circumstances
where homeostasis is affected by environmental stresses or due to genetic alterations, chaperone
proteins help to stabilize the system. Molecular chaperones facilitate the assembly, disassembly
and/or folding/refolding of cytoskeletal proteins, so they prevent aberrant protein aggregation.
Nonetheless, the roles of heat-shock proteins and immunophilins are not limited to solve abnormal
situations, but they also have an active participation during the normal differentiation process of
the cell and are key factors for many structural and functional rearrangements during this course of
action. Cytoskeleton modifications leading to altered localization of nuclear factors may result in
loss- or gain-of-function of such factors, which affects the cell cycle and cell development.
Therefore, cytoskeletal components are attractive therapeutic targets, particularly microtubules, to
prevent pathological situations such as rapidly dividing tumour cells or to favor the process of cell
differentiation in other cases. In this review we will address some classical and novel aspects of
key regulatory functions of heat-shock proteins and immunophilins as housekeeping factors of the
cytoskeletal network.
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Cytoskeleton is the basic scaffold of the cell in which other subcellular components are
spatially arranged, such that they are able to communicate efficiently between the internal
and external environments of the cell. Although the folding system of this assortment of
filamentous and tubular polymers composed of microtubules, microfilaments and
intermediate filaments was discovered more than two decades ago, our understanding of the
complex quality control pathway of these structures is still poorly understood and there are
many unanswered questions that remain to be elucidated. The cytoskeleton is incomplete
without its associated proteins. The proteins known to closely communicate with the
cytoskeletal network include molecular chaperones that appear to protect the cytoskeleton in
circumstances where cytoskeletal homeostasis is affected.
Molecular chaperones were first described as preferentially synthesized factors in organisms
exposed to heat or other physiological stresses. In an attempt to restore cellular function
under these conditions, some molecular chaperones prevent denaturation of proteins while
others may dissociate protein aggregates, refold monomers, oligomers or simply direct them
to their proteolytic cleavage. Nevertheless, chaperones are also synthesized constitutively
and, under normal conditions, they also exert cardinal functions in the organization of the
structures of the cell as well as in the functional efficiency of several signaling cascades. In
this review it is analyzed the relationship between molecular chaperones and the
organization of the structure and function of the cytoskeleton.
1. The cytoskeleton
The cytoskeleton constitutes the structural support of the living matter. It also plays key
functional roles in the life time of the cells and during their replication. The cytoskeleton is
present in all eukaryotic cells and was once thought to be an exclusive structure of
eukaryotes, but homologues of the major scaffold proteins of the eukaryotic cytoskeleton
have also been found in prokaryotes [1, 2]. The cytoskeleton is a dynamic three dimensional
filamentous structure that fills the cytoplasm maintaining the cell shape, enables the cell to
move, and plays cardinal roles in the intracellular transport of vesicles, organelles and
soluble proteins, during the cell division, the segregation of chromosomes, maintenance of
proper cell shape, cell polarity and assembly of intracellular organelle-like structures. The
three types of cytoskeletal elements that have been characterized in eukaryotic cells are
tubulins, actins, and intermediate filaments (IFs).
1.1. Tubulin
Tubulin forms microtubules of about 25 nm in diameter consisting of straight 13
protofilaments that assemble into hollow tubules through lateral contacts to both sides of the
protofilaments [3]. The cylinder yields a helical arrangement in which each turn of the helix
spans three tubulin monomers (e.g., α, β, α). This generates a seam in the microtubule wall
where, instead of the predominant αα and ββ lateral contacts, subunits are laterally adjacent
to β subunits. Microtubules are organized from the minus end (in close vicinity with the
centrosome) and extend through association of GTP-bound α-tubulin and β-tubulin
heterodimers onto the plus end, which faces the cell periphery. The dimers are released from
the minus end after hydrolysis, which destabilizes the intrafilament contacts. However,
microtubules can rapidly release dimers from both ends and thus shrink, a stochastic event
called catastrophic collapse, giving rise to dynamic instability of the filaments. Thus,
tubulin filaments are highly dynamic elements within the cells. γ-Tubulin, which is
homologous to α and β tubulins, nucleates microtubule assembly within the centrosome in a
structure called microtubule organizing center (or MTOC). Around 12 to14 copies of γ-
tubulin associate in the complex with other proteins called GRIPS (for gamma-ring
proteins), this complex being capped at one end and thought to be the minus end terminal.
Microtubule polymerization at this end is inhibited, and the GRIP proteins of the cap may be
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involved in mediating binding to the centrosome. Phosphorylation of a conserved tyrosine
residue of γ-tubulin has been shown to regulate microtubule nucleation [4]. In vertebrate
cells, but not in plants, a specific microtubule-based organelle is embedded within the
organizing center, the centriole.
Microtubules set up the tracks of the mitotic spindle apparatus that are used to segregate
chromosomes during mitosis and meiosis through dedicated motor proteins. Microtubules
are key actors in organizing the spatial distribution of organelles in interphase cells, are
stable components of cilia and flagella, and also serve to provide tracks for the transport of
intracellular vesicles and other cargoes that are moved through cells by motor proteins such
as dynein and kinesin, which show predominant retrograde and anterograde direction of
movement on microtubules.
1.2. Actin
Actin forms a two-stranded, right-handed helical filament of about 7 nm in diameter with an
axial rise of 5.4 nm per monomer that has a plus-/minus-end polarity and is also dynamic
[5]. Owing to filament asymmetry, ATP-bound actin adds to the plus end (often called the
barbed end) much faster than it does to the minus end (also called the pointed end). ATPase
activity leads to conversion to ADP-actin within the filament, and ADP-actin is released at
the minus end. This process is called tread-milling and leads to a net polymerization at one
end and depolymerization at the other end. Thus, while the center of the filament (and each
subunit) remains stationary, the tip of the filament can push objects by limiting them in their
diffusion, such that they can diffuse only in the direction of the extended filament. Actin
polymerization is required for cell movement via extension of pseudopods, where other
additional proteins induce branching of actin filaments generating a network that pushes
against the leading edge of the membrane in a brush-like manner [6]. Actin is also required
for the movement of some types of vesicles through cells [7].
In addition, actin is a contractile protein and one of the most abundant proteins in cells. In
muscle cells, the association of microfilaments with myosin is responsible for muscle
contraction. Microfilaments can also carry out cellular movements including gliding,
contraction, and cytokinesis. They are mostly concentrated just beneath the plasma
membrane, as they keep cellular shape, form cytoplasmatic protuberances such as
pseudopodia and microvilli, and participate in cell-to-cell or cell-to-matrix junctions and in
the transduction of signals. Recently, it was demonstrated the existence of a subset of
actomyosin fibers that form a perinuclear actin cap, a cytoskeletal structure that tightly
wraps around the nucleus [8]. Fibers in the actin cap are distinct from the conventional actin
fibers at the basal and dorsal surfaces of adherent cells in their organization, dynamics,
response to cytoskeletal pharmacological treatments and biochemical stimuli, and response
to disease-associated mutations of lamins A/C. The perinuclear actin cap precisely shapes
the nucleus in interphase cells and is a mediator of microenvironment mechanosensing and
mechanotransduction, as well as a regulator of cell motility, polarization and differentiation
[8, 9].
1.3. Intermediate filaments
IFs are composed of extended coiled-coil proteins that assemble into rigid sheets. IFs form
8- to 10-nm-thick cytoskeletal elements that provide internal mechanical support for the cell
and position different organelles [10, 11]. They form a large superfamily of proteins
containing 73 gene products [12] that are expressed in tissue-, cell-, differentiation-, and
development-dependent manners, and are related to more than 90 human pathologies
(www.interfil.org). Different kinds of IFs share similar basic characteristics. IFs provide the
tensile strength of a cell and determine its internal structure; for example, they are structural
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components of the nuclear envelope and of the sarcomeres and participate in some cell-cell
and cell-matrix junctions [13].
IFs are classified in six types. Type I and II are acidic and basic keratins, respectively, and
form the cytoskeleton of epithelial tissues, skin-hair, nails, and horns. Many intermediate
filaments are made of vimentins, a type III IF that is highly abundant in mesenchymal cells,
such that it is often used as marker of mesenchymally-derived cells or cells undergoing an
epithelial-to-mesenchymal transition during both normal development and metastatic
progression [14]. Also, vimentin is found to control the transport of low-density lipoprotein-
derived cholesterol from lysosomes to the esterification sites [15]. The type IV family of IFs
shows neurofilaments as filament archetype. Neurofilaments are found in high
concentrations in the axons of vertebrate neurons associated to some IFs that copurify with
them such as α-internexin. Some muscle-specific filaments such as syncoilin and synemins
are also clustered into this type of IF. Type V filaments are the lamins, fibrous proteins that
give structural support to the nuclear envelope. Finally, type VI IF comprise nestins, whose
expression has been extensively used as a marker for central nervous system progenitor cells
based on observations indicating a correlation between nestin expression and this cell type in
vivo [16]. Its expression is usually transient and upon differentiation, nestin becomes down-
regulated and is replaced by tissue-specific IFs, e.g. neurofilaments and glial fibrillary acidic
protein (GFAP) during neurogenesis and gliogenesis.
IFs are much less conserved in sequence than are tubulins or actin, because different
sequences can make up coiled-coil motifs. IFs display a tripartite structure consisting of an
α-helical central rod flanked by non-helical head and tail domains, and assemble to give rise
to nuclear (lamins) or to different cytoplasmic IF networks such as keratins, vimentin,
neurofilaments, peripherin, desmin, and GFAP [17–19]. IFs are regulated by both post-
translational modifications and through interactions with multiple IF-associated signaling
cascade proteins such as 14-3-3 proteins, apoptosis-related proteins, kinases and
phosphatases [20, 21], all of them being processes that may affect from IF solubility to
sensitivity to be degraded by caspases or proteosomal degradation. Unique functional roles
for IFs also include protection from mechanical stress sharing cytoprotective roles with
associated heat-shock proteins to inhibit apoptosis, regulate organelle homeostasis, and
scaffolding [19].
1.4. Prokaryotic cytoskeleton
Before the 90’s, the cytoskeleton was thought to have evolved only in eukaryotes. However,
cytological techniques developed for eukaryotic cells were adapted and used for the study of
the cellular organization of bacteria and archaea, revealing that these organisms also contain
a number of subcellular counterparts of actin, tubulin, and IF proteins [2, 22–24]. FtsZ was
the first of these proteins to be identified. Like tubulin, FtsZ forms filaments in the presence
of GTP, although the filaments do not group into tubules. During cell division, FtsZ moves
to the division site and recruits other proteins required to generate a new cell wall between
the dividing cells. On the other hand, MreB is considered the prokaryotic actin-like protein.
As such, it is involved in maintaining cell shape. Non-spherical bacteria also encode other
actin-like proteins that form a helical network beneath the cell membrane, which in turn
guides the proteins required for the synthesis of a new cell wall. Other actin-like protein is
ParM, whose filaments participate in the division of plasmidic DNA into the daughter cells
by a mechanism similar to that used by microtubules during eukaryotic mitosis. Finally,
crescentin is a bacterial counterpart related to IFs of eukaryotic cells and is involved in
maintaining cell shape.
Cytoskeleton proteins of both eukaryotic and prokaryotic cells require the assistance of
associated factors for the maintenance of their structures and functions. In this regard,
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molecular chaperones are essential for this process. This is not surprising if three essential
facts are considered: a) there is a structural similarity between actins and the Hsp70 class of
molecular chaperones [25, 26]; b) heat-shock has deleterious effects on the internal
organization of the cell beyond the unfolding of individual proteins and, especially in
eukaryotes, one of the major damages observed in response to stress conditions are defects
of the cytoskeleton and loss of the proper localization of organelles and breakdown of
intracellular transport processes; and c) prokaryotic heat-shock proteins have been preserved
during the evolution and show high structural homology with their eukaryotic patterns to the
point that most of them can be functionally exchanged.
2. Molecular chaperones
Socially speaking, the term chaperone refers to a person (as a matron) who used to
accompany young unmarried women in public or supervise young people at a social
gathering to ensure proper behavior. By analogy, those proteins that assist others in their
proper folding and biological functions are referred to as chaperones (e.g. Hsp90 or Hsp70).
The term ‘molecular chaperone’ was first used to describe the ability of nucleoplasmin to
prevent the aggregation of histones with DNA during the assembly of nucleosomes, and was
extended to describe proteins that mediated the post-translational assembly of protein
complexes (see an appealing background in Ellis review [27]). The term co-chaperone,
sometimes wrongly employed as synonym of chaperone, refers to proteins that assist
chaperones or are associated to them favoring the properties of the client-protein (e.g. p23 or
FKBP52). Normally, co-chaperones are non-client-binding partners, although they may
themselves have chaperone activity as well. Chaperonines are protein complexes that assist
the folding of nascent non-native polypeptides into their native functional state (e.g. Hsp10/
GroES, TRiC/CCT). All these proteins, chaperones, co-chaperones and chaperonines,
belong to a larger class of molecules that assist protein folding, the molecular chaperones,
whose major function is to prevent both newly synthesized polypeptide chains and
assembled subunits from aggregating into nonfunctional structures. It is for this reason that
many chaperones, but by no means all, are also heat-shock proteins (Hsp) since the tendency
to aggregate increases as proteins are denatured by stress.
2.1. Heat-shock proteins
The term “heat-shock protein” stems from the original observation that heat-stress greatly
enhances the production of a specific class of proteins, subsequently identified as molecular
chaperones. The Hsp family comprises five major and broadly conserved subfamilies—
Hsp100s, Hsp90s, Hsp70s, Hsp60s, and small heat shock proteins (sHsps). Several other
heat-inducible molecular chaperones, like Hsp33 [28] are also part of the family, but since
they are not ubiquitous, they were not included in a separate subfamily. Because the stability
of cellular proteins is relatively low and aggregation competes with their efficient folding,
even at physiological temperatures, there is a constant need for chaperone assistance during
de novo protein folding and refolding of non-native polypeptide chains [29, 30]. What
discriminates a native protein from its non-native unfolded (partially or globally) counterpart
is the exposure of hydrophobic residues, which are recognized by molecular chaperones.
Normally, binding to hydrophobic patches, specific peptide sequences, or structural
elements of the non-native protein takes place to protect these proteins from aggregation and
degradation. Generally, molecular chaperones do not contribute to the structural information
for protein folding, but prevent those unwanted intermolecular interactions. Chaperones do
this through controlled binding and release of non-native proteins, which is usually
accomplished by a change of the affinity of the chaperone for its client substrate. This
exchange between two or more affinity states is controlled by the binding to the chaperone
and/or subsequent hydrolysis of ATP molecules, with the sole exception of sHsps. The latter
chaperones are optimal for an efficient first line of defense. This is why these low molecular
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weight chaperones are also known as holdases. On the other hand, the foldases come in
stress-induced and constitutively expressed versions (e.g., Hsp70 versus Hsc70).
2.1.1. Hsp90—Hsp90 is the major soluble cytosolic protein that is expressed under both
normal (2–3% of the total) and stressful conditions (6–10% of the total) [30–33]. In
mammals there are two isoforms, Hsp90α and Hsp90β, encoded by separate genes and
usually forming homodimers [34]. It is primarily a cytosolic protein, but a small portion
rapidly accumulates in cell nuclei upon stress. It is a phosphoprotein containing two to three
phosphate molecules per monomer, which is thought that enhances its function. Hsp90 is
evolutionarily conserved among species, and is proven essential for cell survival. Its
contribution to various cellular processes, including signal transduction, protein folding and
degradation, and morphological evolution, has been extensively studied and reviewed [31,
35–39]. Its analogues include Grp94 in the endoplasmic reticulum and Hsp75/TRAP1 in the
mitochondrial matrix.
Hsp90 displays a relatively weak ATPase and chaperoning activity, i.e., prevention of
aggregation of unfolded polypeptides and assistance in their refolding. It is more selective
than other chaperones and chaperonines for the recognition of its substrates and shows low
affinity for unfolded proteins. Actually, its principal role in the cell is to provide biological
activity to properly folded client proteins with a preserved tertiary structure and functions as
a delicate and refined sensor of protein function rather than a gross folding factor. In
particular, the cooperation of Hsp90 with other chaperones such as the Hsp70/Hsp40
complex and cochaperones such as p23 and immunophilins (IMMs) makes a vital
contribution to the maturation of signal-transduction proteins such as steroid receptors and
protein-kinases [36]. Thus, highly orchestrated interactions between the immature, low
affinity steroid receptor protein and the Hsp90-based heterocomplex is required to shape the
mature and biologically active forms of the receptors that trigger steroid signaling [36, 40].
Importantly, the Hsp90•FKBP52 complex is responsible for the retrotransport of soluble
factors using microtubules as cellular tracts [33, 41, 42]. This interaction is possible thanks
to the presence of a TPR-acceptor site in the Hsp90 dimer.
In addition to TPR-domain co-chaperones, Hsp90 also shows other co-chaperone binding
site for the small acidic cochaperone p23. It comprises the N-terminal ATP-binding site plus
a downstream domain, all in an Hsp90-dimer arrangement.[43]. It enters at a late stage of
the cycle and enhances the maturation of client proteins stabilizing their interactions with
Hsp90. Dimers of Hsp90 are in dyamic equilibrium between two states, the ADP-bound
isoform and the ATP-bound isoform (Fig.1). The ADP-bound Hsp90 shows higher affinity
for a TPR-domain cochaperone named Hop (heat-shock organizing protein) that brings
together Hsp70 and Hsp90 (this is the genesis of its name) and also influences the
functioning of Hsp90. Hop binding to Hsp90 blocks ATP binding and the ATPase activity of
the chaperone, and this inhibits very effectively the binding of the cochaperone p23 [44, 45].
Such ADP-bound conformation of Hsp90 is favored by the Hsp90 disrupting agent
geldanamycin, which shows high affinity by the nucleotide binding site of the chaperone.
Geldanamycin prevents the entry of both p23 and TPR-domain immunophilins to the
complex, and consequently, inhibits the major chaperoning activity of Hsp90. On the other
hand, when ADP is exchanged by ATP, this ATP-bound isoform of Hsp90 is stabilized by
p23 binding and other TPR factors such as IMMs are efficiently recruited (Fig.1). The ATP-
bound isoform of Hsp90 is a better modulator of the biological activity of client factors. In
this regard, it appears that p23 binding to Hsp90 changes the environment of the ATP bound
to Hsp90 and prevents the intrinsic ATPase activity of the chaperone [46], which in turn
affects the biological activity of the Hsp90-bound client factor.
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In addition to this stabilizing function, p23 also shows independent functions, the most
surprising being its cytosolic activity of glutathione-dependent prostaglandin E2 synthase
[47]. It has been shown in mice that p23 is not essential for prenatal development and
morphogenesis, but it is absolutely necessary for perinatal survival [48]. Thus, p23−/− mice
show an incomplete skin barrier, the lungs display underdeveloped airspaces and
substantially reduced expression of surfactant genes. This correlates with the known
function of glucocorticoids in promoting lung maturation and the role of p23 in the assembly
of a hormone-responsive GR•Hsp90 complex. Thus, p23 contributes a non-redundant,
temporally restricted, and tissue-specific function during mouse development.
2.1.2. Hsp70—The Hsp70 subfamily of chaperones is the most conserved of the entire
family. Human Hsp70 also shows two isoforms —Hsp72 (gene name HspA1), which is
inducible upon the onset of stressing conditions, and the other, more properly named Hsp73
or Hsc70 (heat-shock cognate-70), is constitutive (gene name HspA8). Human Hsc70 has
85% identity with human Hsp72. Unlike canonical heat-shock proteins that prevent the
aggregation of unfolding proteins and can refold aggregated proteins, Hsc70 is constitutively
expressed and performs functions related to normal cellular processes. Hsc70 was placed in
the heat-shock protein family due to homology with other heat-shock proteins, but the
biological functions of both isoforms differ. A good example is the case of the murine
epithelial sodium channel, whose surface expression and function are decreased by Hsc70,
whereas both properties are favored by Hsp70 [49].
The activity of Hsp70s is regulated by cofactors, the most important being Hsp40. The J-
domains of these proteins interact with the ATPase domain of Hsp70 and stimulate the
hydrolysis of bound ATP [50]. The release of nucleotide and substrate is further accelerated
by nucleotide-exchange factors. It was originally shown that Hsp70 and Hsp40 are required
for ubiquitin-dependent degradation of short-lived and abnormal proteins [51]. The
overexpression of the Hsp70/Hsp40 complex decreases the level of abnormal proteins and
improves viability in cellular models of certain neurodegenerative diseases characterized by
the accumulation of aberrant proteins, such as Parkinson’s disease, Huntington’s disease,
and spinal and bulbar muscular atrophy [52–56].
It was originally thought that both Hsp90 and Hsp70 worked to promote refolding of
proteins that aggregated in stressed cells, but it has subsequently become clear that it is
Hsp70 the chaperone that focuses unfolded proteins on proteasomal degradation, whereas
Hsp90 shows a protective role, as it is suggested by the fact that its inhibition with
geldanamycin promotes protein degradation.
2.1.3. TPR-Domain Immunophilins—Immunophilins (IMMs) comprise a family of
intracellular proteins with peptidyl-prolyl-cis/trans-isomerase (PPIase) activity, i.e.,
cis↔trans interconvertion of Xaa-Pro bonds. IMMs are classified by their ability to bind
immunosuppressant drugs –cyclophilins bind cyclosporine A, and FKBPs (FK506-binding
proteins) bind FK506 [36, 57]. The signature domain of the family is the PPIase domain.
Only the low molecular weight immunophilins FKBP12 and CyPA are related to the
immunosuppressive effect when the drug•IMM complex inhibits the Ser/Thr-phosphatase
activity of PP2B/calcineurin. High molecular weight IMMs have three additional domains –
the nucleotide-binding domain, where ATP binds, the calmodulin-binding domain, a poorly
characterized domain able to interact with calmodulin, and TPR domains, through which
they bind to Hsp90 [58]. See Fig.3A in advance for a comparative scheme of the structures
of FKBP51 and FKBP52 (the functional properties will be addressed later on in the topic 4).
TPR-domain IMMs are abundant and ubiquitous proteins that were first discovered
associated to steroid receptors. To date, the biological function of these proteins is poorly
understood. In 2001, it was reported that the dynein/dynactin complex binds to FKBP52
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favoring the glucocorticoid retrotransport [59]. Complexes of IMMs and motor proteins
have also been related to other proteins’ trafficking, such as mineralocorticoid receptor [60],
androgen receptor [61], p53 [62], the AIF/Rac3 complex [63], adeno-associated virus 2 [64],
etc., suggesting that factors able to interact with the hsp90•FKBP52 complex could share a
similar molecular machinery of movement. The low molecular weight IMM CyPA also
interacts with dyenin and it is thought to participate in viral particles transport [65]. The
biological function on protein trafficking of IMMs associated to heat-shock proteins is not
limited to the cytoplasm. Once the cargo has reached the nuclear envelope using
microtubules as molecular tracks, it must traverse the nuclear pore. The Hsp90 complex,
including FKBP52 (but not the highly homologous partner FKBP51), interacts with the
nuclear import machinery of nucleoporins and importins facilitating the nuclear import of
cargoes [32].
Most TPR-domain IMMs can interact with motor proteins [66], but this property or the
ability of favoring the retrotransport of proteins is also shared by some low molecular
weight cyclophilins [65, 67]. Nonetheless, the best characterized are the TPR-domain IMMs
because they were found associated to the steroid receptor•Hsp90 complex, in particular
FKBP52 and FKBP51. These two IMMs show 60% identity and 75% similarity [68]. They
bind hsp90 via TPR domains, contain an active PPIase domain, and adopt similar
conformations according to X-ray crystallography images [69, 70]. Nonetheless, their
functions differ drastically. FKBP52 is a positive regulator of the activity of the
glucocorticoid receptor, progesterone receptor and androgen receptor, whereas FKBP51 has
generally been regarded to be a negative regulator of steroid receptor activity as its
overexpression prevents the regulation by FKBP52 due to its competition for binding to the
receptor complex. Importantly, while FKB52 itself is able to interact with cytoskeletal
structures [71–73] and links steroid receptor with microtubules, FKBP51 does not show
these properties. Perhaps related to these features, it was shown recently that the macrolide
FK506 promotes neuroregeneration via FKBP52, the early subcellular relocalization of
FKBP52 being required for the efficient outgrowth of neurites [74], whereas FKBP51
antagonizes the effects of FKB52. Thus, binding of these TPR proteins to Hsp90 complexes
could show inhibitory or stimulatory action of the client protein, which in turn regulates
diverse aspects of the cell physiology [60, 75].
2.1.4. Hsp25/27—Human Hsp27 (or mouse homologue Hsp25) belongs to the family of
sHsps, which includes nine other isoforms [76]. All these proteins contain a highly
conserved region referred to as the α-crystallin domain, which contains high percentage of
β-sheets. Hsp25/27 is an ATP-independent chaperone not only implicated in protein folding,
but also in shaping the architecture of the cytoskeleton, cell migration, metabolism, cell
survival, growth/differentiation, mRNA stabilization, and tumour progression. A variety of
stimuli induce phosphorylation, p38 MAP kinase being the most efficient kinase.
Phosphorylation of Hsp25/27 favors the dissociation of multimers, which is part of the
mechanism providing protection against the negative effects of diverse stress factors. The
native size of oligomers is critical, such that the large non-phosphorylated Hsp25/27
oligomers show the greatest protective potential against the adverse effects of tumour
necrosis factor-α or reactive oxygen species. Under normal conditions, phosphorylated
Hsp25/27 exerts anti-proliferative and antiapoptotic effects and is involved in actin filament
dynamics. Anomalous Hsp27 phosphorylation was correlated to pathologies such as viral
infections, specific tumour cells, autoimmune diseases, nephropathies, etc. [76].This sHsp
modulates the assembly of IFs, participates in the actin polymerization/depolymerization
process, and inhibits the aggregation of tubulin [77]. Hsp25/27 prevents actin
polymerization when bound, and phosphorylation induces a conformational change resulting
in dissociation from the barbed ends of the actin filaments, thus freeing them for the addition
of actin monomers [78]. Its overexpression stabilizes microfilaments against deleterious
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effects of hyperthermia and cytochalasin [79]. Accordingly, inhibition of kinase activity that
results in Hsp27 phosphorylation or expression of a non-phosphorylable mutant Hsp27 in
the fibroblasts inhibits the filament stabilization and inhibits processes dependent on a
dynamic microfilament cytoskeleton (e.g., membrane ruffling and pinocytosis) [80].
2.1.5. Chaperonines—Chaperonines are ring-shaped chaperones that encapsulate non-
native proteins in an ATP-dependent manner. In bacteria, the most prominent chaperonin is
the GroE machinery, which consists of fourteen GroEL subunits arranged in a cylinder of
two heptameric rings, to which the cochaperone GroES, also a heptameric ring, binds [81].
The closely related proteins in mitochondria are called Hsp60 and Hsp10. Non-native
protein chains up to 60-kDa are bound in the central cavity of the GroEL cylinder, and the
cavity is then closed by the binding of the GroES cofactor in the presence of ATP. As a
result, the client protein may fold or it could gain their native structure after release from
GroE, depending on the folding properties of the respective protein. Therefore, a GroE-
bound protein can be refolded isolated from other non-native polypeptide chains, a wise
mechanism that prevents massive aggregation. Such a potent protein-folding machine,
which is essential in bacteria, should also have enormous importance for the proper
management of stressing situations in eukaryotic cells. However, there is no GroE in the
eukaryotic or archaeal cells. Nonetheless, the GroE function has been replaced by a distant
relative machinery, the CCT (chaperonin-containing the T-complex polypeptide-1), also
named TRiC (tailless complex polypeptide 1-ring complex), whose architecture and function
resembles that of GroE. The CCT/TRiC machinery is the eukaryotic cytoplasmic chaperonin
essential for growth of worms and yeasts. Mutations in individual subunits affect assembly
of tubulin and actin [82] and have been implicated in neurodegenerative diseases [83, 84].
The main cellular function of CCT/TRiC is to promote the folding of newly synthesized
polypeptides, which may be presented by Hsp70 and/or the cochaperone prefoldin [85, 86].
Perhaps due to this reason, CCT/TRiC is not induced by stress, but is instead
transcriptionally and functionally linked to protein synthesis [87]. CCT/TRiC forms a large
complex composed of eight homologous subunits arranged in two octameric rings stacked
back-to-back that form a 1-MDa complex that functions like a cage for protein folding to
occur unimpaired by aggregation. Whereas all CCT/TRiC subunits have essentially identical
ATPase domains, their polypeptide-binding regions have significantly diverged during
evolution to create substrate binding specificity. As a result, a diverse set of polypeptide
substrates, estimated to be 5–10% of newly synthesized cytoplasmic proteins, including
actin and tubulin, flux through CCT/TRiC [88]. Actually, due the relative abundance of
tubulin and actin, it is thought that a substantial proportion of CCT/TRiC is always occupied
by these proteins [89]
3. Shaping the cytoskeletal architecture
3.1. Role of heat-shock proteins
A small increase in temperature cause rapid and significant protein unfolding along with
entanglement of cell architecture and, in a relatively extreme situation, non-specific
aggregation of proteins. Therefore, many of the morphological and phenotypic effects of
heat stress could be explained as a side effect of the aggregation of proteins with the
consequent loss of protein homeostasis. In other words, it is reasonable to assume that the
deleterious accumulation of improperly folded proteins is a signal that must trigger
homeostatic countermeasures, which indirectly implies that the cell itself could not
recognize changes of temperature as such, but via the balance between molecular
chaperones and unfolded proteins. There is a plethora of stresses beyond the heat-shock that
trigger similar responses, such as metabolic toxics, oxidations, heavy metals, ethanol,
irradiation, glucose deprivation, disturbance of calcium homeostasis, etc. One of the major
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damages observed in response to most of these stress conditions are defects of the
cytoskeleton.
Mild heat stress leads to the reorganization of actin filaments into stress fibers, while severe
heat stress results in the aggregation of vimentin or other filament-forming proteins, leading
to the collapse of intermediary, actin, and tubulin networks. Along with the disruption of the
cytoskeleton, the loss of the correct localization of organelles and a breakdown of
intracellular transport processes are also observed. The cytoskeletal network is not
independent for the different types of filaments. When microfilaments are inhibited at the
periphery of the cell, an immediate response is the depolymerization of microtubules from
the cell edge [90].
Unlike heat-shock proteins, changes in IF levels in response to stress are dependent on both
the tissue and gene involved. For example, the astrocytic GFAP expression remain unaltered
after heat exposure [91], while vimentin is heat-sensitive since it is elevated in non-neuronal
cells and in the microvasculature of the hippocampus [92], but it is diminished in heat-
exposed rat embryos [93] whose de novo synthesis of Hsp70 and Hsp90 is very rapidly
induced (1–8 h after exposure) [94]. Hsp70 is thought to participate in de novo folding
pathways of cytoskeletal proteins along with their cognate chaperonines [95]. Notably, the
mechanism in eukaryotes involves a physical interaction between Hsp70 and CCT/TRiC
near the opening of the chaperonin cavity, indicative of a direct hand-off of substrates [96].
It is unclear whether or not nascent actin and tubulin proteins use the Hsp70 chaperone
under certain circumstances.
Heat reduces the extent of microtubule nucleation with significant loss of the centrosomal
markers γ-tubulin and pericentrin, and dynamitin, the 50-kDa subunit of the dyenin/dynactin
complex [97]. Nonetheless, heat-shock proteins are recruited to the centrosomes with
protective purposes [98], such that in thermotolerant cells, the length of heat shock-induced
mitotic delays and the frequency of heat shock-induced division errors are reduced with the
close association of Hsp70, but not Hsp27 or Hsp40, with centrosomes. Moreover, the
overexpression of Hsp70 restores the localization of dynamitin/p50 at centrosomes and
protects cells against most heat-induced mitotic abnormalities [97].
Hsp90 also protects tubulin against thermal denaturation and keeps it in a state compatible
with microtubule polymerization [99]. While Hsp90 cannot resolve tubulin aggregates, the
chaperone binds early unfolding intermediates preventing their further aggregation.
Protection is maximal at a stoichiometry of two molecules of Hsp90 per molecule of tubulin
and does not require ATP, although it is counteracted by specific Hsp90 inhibitors such as
geldanamycin. Fig.2 shows an integrated scheme depicting most of the housekeeping roles
of the chaperones that have been discussed in this topic regarding the structural integrity of
microtubules and microfilaments (refer to the figure legend for details). Note that due to
reasons of simplicity of the scheme, chaperones and IMMs were not included in all the
steps, but they are actually characters of each process.
More generally, besides stress conditions, it is known that microtubules reorganize at the
interphase-mitosis (G2/M) transition leading to the decrease of the cellular microtubule
quantity [100]. Concomitantly, the cytosolic concentration of free tubulin temporarily
increases, such that at this point of the cell cycle, Hsp90 can participate in maintaining
tubulin dimer integrity and making it available to form the mitotic spindle.
A significant fraction of Hsp90 is also associated to microfilaments along with its
cochaperone p23 [101]. When cells are treated with colcemid under conditions that
eliminate microtubules, these chaperones condense into bright rope-like bundles located in
the immediate perinuclear area and extending toward the cell periphery. Identical images are
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observed with an antibody against vimentin and the pattern seen after colcemid treatment is
classical for IFs. Heat-shock causes the spatial arrangement of IFs to change from a fine
thread-like network to a large, perinuclear aggregate, whereas in thermotolerant cells,
integrity of the IF network is enhanced, and maintenance of this organization is required for
establishment of increased heat resistance [102].
When brain tumour cells are treated before heat-shock with angulatin-A, a drug that disrupts
vimentin intermediate filaments, they do not acquire thermotolerance, while those treated
after receiving a heat-shock gain protection. The vimentin intermediate filaments in cells
exposed to the drug prior to heating are arranged in tight perinuclear aggregates unable to
return to their normal distribution upon recovery. In contrast, IFs in cells treated with the
drug subsequent to thermal stress resume a dispersed organization. Hsc70 colocalizes with
vimentin during these spatial changes, most likely favoring IF stabilization. Importantly,
during the very early steps of neuronal differentiation, p23 concentrates in filaments that
colocalizes with neurofilaments [103].
3.2. Hsp90, microtubules and disease
The association of Hsp90 with microtubules shows several implications. Many proteins
responsible for malignant progression within tumour cells are Hsp90-dependent and dozens
of oncogenic substrates have been identified to date. Hsp90 regulates pathways that fulfils
the six hallmarks of cancer [104], i.e. evasion to apoptosis (Apaf-1, NF-κB, p53, survivin,
etc.), sustained angiogenesis (VEGF, VEGFR, Src, HIF-1α, etc.), tissue invasion (MMP2,
urokinase, BRMS1, etc.), self-sufficiency in growth signals (Raf-1, Her2, MEK, Bcr-Abl,
etc.), insensitivity to anti-growth signals (Weel, CD4, cyclin D, Plk, etc.), limitless
replicative potential (telomerase). Therefore, targeting Hsp90 can offer a unified mechanism
for chemotherapy. In addition, Hsp90 is overexpressed in malignant cells, and its expression
correlates with the proliferation of these cells [105]. Hsp90 inhibitors represent a unique
class of compounds that demonstrate high differential selectivity for malignant versus
normal cells at concentrations that are well tolerated by humans [31, 106, 107]. There are
currently twenty Hsp90-targeted clinical trials in progress and many more inhibitors are in
preclinical development, in particular, geldanamycin-derivatives.
Recently, it was shown that Hsp90 inhibits tubulin aggregation and that tubulin
polymerization is slower in the presence of Hsp90 than in its absence [99], indicating that
the polymerization state of microtubules depends on the cell type and the stress conditions.
Hsp90 sequesters soluble (i.e. unstable) tubulin dimers to prevent their irreversible
aggregation and to maintain them in a conformational active state for several hours. Once
the stress conditions have ended, tubulin is able to form microtubules again, thus, restoring
their cellular functions. As it is expected, inhibitors of Hsp90 prevent this action and
unstabilize the cell due to microtubule disassembly.
Taxol is a well-known drug for the treatment of cancer that is responsible for the
stabilization of microtubules and inhibition of mitosis. Interestingly, taxol induces
transcription factors and kinase activation, mimicking the effect of bacterial
lipopolysaccharide (LPS), an attribute unrelated to its tubulin-binding properties [108].
Actually, a significant amount of evidence suggests that the LPS-mimetic activity of taxol is
independent of β-tubulin binding. Affinity chromatography experiments with lysates from
both mouse brain and macrophage cell lines led to affinity purification of two chaperones,
Hsp70 and Hsp90 [109]. In contrast to typical Hsp90-binding drugs, taxol exhibits a
stimulatory response, mediating the activation of macrophages and exerting LPS-mimetic
effects. The geldanamycin derivative 17-AAG behaves synergistically with taxol-induced
apoptosis due to sensitization of tumour cells by suppression of Akt [110], a Ser/Thr protein
kinase that is stabilized by Hsp90, as well as its activating kinase PDK1 [111]. Therefore,
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the potential use of Hsp90 inhibitors in combination with proapoptotic therapies represents
an exciting new strategy for chemotherapy.
3.3. Survivin complexes with Hsp90
The effect on microtubule inhibition is most prominent in mitotic cells where mitotic
spindles play a key role in chromosome segregation, and this is why these types of drugs
have been classified as anti-mitotic agents. Some chaperone factors such as the Hsp90 client
protein surviving are known to localize to the mitotic spindle by interaction with tubulin
during mitosis and regulate mitosis [112]. The chaperone survivin is known to be expressed
across most tumour cell types and is at the same time absent in normal non-malignant cells,
which transforms this molecular chaperone in a potential therapeutic target. Thus, the
naturally occurring compound resveratrol (a polyphenol found in grapes and red wine) can
be used as a sensitizer for anticancer drug-induced apoptosis by the action of causing cell
cycle arrest [113] that produces a dramatic decline in survivin levels in the cells.
Overexpression of survivin has been shown to induce drug resistance against anti-mitotic
compounds by stabilizing microtubule network in vincristine/colchicines-resistant oral
cancer cells and down-regulation of it restores drug sensitivity [114]. Because Hsp90 binds
and stabilizes survivin [115], down-regulation of survivin could be one of the important
therapeutic functions of Hsp90 inhibitors such as geldanamycin derivatives. However, a
recent report shows evidence that surviving is actually induced by Hsp90-inhibitors [116].
Survivin is a also a dual functional protein since it blocks apoptosis by inhibiting caspases,
but it also promotes cancer cell growth by stabilizing microtubules during mitosis. In short,
the properties of the Hsp90•survivin complex is far from being clear.
Hsp90 associated with survivin is also overexpressed in cancers [117]. It is thought that the
cytoprotection mechanism of this Hsp90•survivin association is centered on the
mitochondrial pathway, where surviving has a role in the regulation of mitochondrial
apoptosis specifically in tumours [115]. The disruption of the survivin•Hsp90 complex
destabilizes surviving leading to mitochondrial apoptosis and ultimately cell growth
suppression. However, Hsp90 interaction with survivin also enables stabilization of
cofactors such as AKT, Erb-2 and HIF-1α, which can lead to tumour progression [116].
Because survivin is also related to cell division due to its association with the mitotic
spindle, there is controversy from the therapeutic point of view regarding how to manage
this molecule. Inasmuch as the molecular chaperone Hsp90 binds and stabilizes survivin, it
is currently accepted that targeting both proteins at the same time could be beneficial, but a
great deal of experimental evidence is certainly required to date to apply in the facts such
strategy.
3.4. Dynamic role of CCT/TRiC
Although αβ-tubulin heterodimers are very stable, the mean half-life of tubulin does not
reflect the fact that tubulin is partitioned into multiple states that could have very different
turnover rates (i.e. chaperone–monomer complexes, GTP- or GDP-bound dimers, dynamic
or stable microtubules, etc.). From the biological perspective, it appears that chaperonin
CCT/TRiC is a major factor responsible for the stability of microtubules. In the absence of
CCT/TRiC function, tubulin cannot fold efficiently and non-native tubulin is removed by
proteolysis [118]. The degree of growth arrest strongly correlates with the extent of CCT/
TRiC depletion, indicating that its full activity is required for normal cell growth and
division. Depletion of CCT/TRiC does not affect actin polypeptide synthesis, but causes a
reduction in levels of native actin and perturbation of actin-based cell motility, and there are
no large-scale effects on cytoplasmic protein synthesis or a general heat-shock response
during periods of low CCT/TRiC activity. The integrity of the entire cytoskeleton is closely
linked to this chaperonin via the folding requirements of actin and tubulin (Fig.2), but the
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role of this chaperonin in cytoskeletal organization remains still unclear. Recent evidence
suggests that some CCT/TRiC monomer subunits can influence cytoskeletal organization
and polymerization, so the biological activity of the chaperonin may extend beyond the
folding of newly synthesized polypeptides, representing other functions for individual
subunits distinct from their role in the oligomer [119].
Stress fibers are known to be dynamic structures with regard to actin turnover rates, and it
has been suggested that when these rates are decreased, the actin filaments become more
prominent [120]. Recent evidence showed that here is a tendency for those fibers with
weaker phalloidin staining to be decorated with selected CCT subunits among the number of
monomers available for this chaperonin [119], so it is possible that these CCT subunits assist
in the addition of new actin monomers onto actin filaments within stress fibers and are
therefore found associated with stress fibers that are more dynamic. CCT is also known to
interact with other proteins that are genuine chaperonin substrates. Recently, the actin
filament remodeling protein gelsolin was identified as a CCT-binding partner [121], and
although it does not behave as a classical cochaperone, gelsolin binds to CCT with a high
specificity. Gelsolin is involved in the transition of tumours from being non-invasive to
invasive [122], which emphasizes the link between cell shape, the actin cytoskeleton, and
the functional relevance of chaperonines.
3.5. CCT/TRiC and disease
It is clear that the cytoskeletal proteostasis machinery will be engaged in rapidly growing
tumour cells and in their response to antitubulin chemotherapeutics. In a novel anti-mitotic
approach, a recent study showed that disrupting the CCT/TRiC•β-tubulin interaction with a
small molecule induces apoptosis even in cancer cells resistant to other tubulin-binding
chemotherapies [123]. CCT/TRiC has another link to cancer whereby its interaction with the
von Hippel–Lindau (VHL) tumour suppressor protein is essential for assembly of the VHL
E3-ubiquitin ligase complex; tumour-inducing mutations in VHL specifically disrupt CCT/
TRiC binding [124]. Bisphosphonates, which are used to treat cancer-induced bone loss (and
which are the subject of clinical trials against breast cancer due to their effects on the
migration, invasion and proliferation of cancer cells) trigger a strong up-regulation of TBCB
and prominent disruption of the microtubule cytoskeleton [125]. Drugs targeting tubulin
folding cofactors could be beneficial because they would be tubulin-specific and could have
anti-proliferative and anti-metastatic effects [126]. Tubulin is degraded in response to
microtubule-destabilizing drugs, so a parallel increase in the concentration of soluble tubulin
is observed. When the function of CCT/TRiC is impaired, tubulin does not fold efficiently
and the non-native tubulin is rapidly removed by proteolysis. Accordingly, treatments of
cells with the proteasome inhibitor MG132 demonstrated that α-tubulin and β-tubulin are
highly ubiquitylated [127]. Moreover, tubulin from various human cell types is targeted by
cancer-preventive isothiocyanates which covalently modify tubulins and induce
conformational changes that trigger proteasome-dependent tubulin degradation [128].
Interestingly, the overexpression of β-tubulin is toxic in Sacharomyces cerevisiae, but α-
tubulin overexpression is well tolerated [129]. However, this particular effect is not
observed in mammalian cells, perhaps due to the autoregulation mechanisms for β-tubulin
degradation.
PolyQ-expanded huntingtin has also been identified as a TRiC substrate [130]. TRiC
partially colocalizes with huntingtin aggregates and remodeled their morphology while
reducing cell death. PolyQ-expanded huntingtin and other amyloidogenic proteins tend to
form fibrillar aggregates possessing a cross-β core with extensive β-sheet structure.
Inasmuch as TRiC substrates tend to be large and are hydrophobic proteins with β-strand
regions of high propensity to aggregate [131], it is therefore plausible that TRiC can regulate
the conformation of huntingtin (and also other amyloidogenic proteins) by direct binding to
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such β-sheet structures formed immediately after the initiation of the aggregation process,
perhaps directly after its synthesis or the proteolytic generation of aggregation prone
fragments.
3.6. Tau protein as a chaperone-assisted factor
Tau is one of several types of microtubule-associated proteins that regulate the assembly and
stability of microtubule networks. It is very abundant in neurons, mostly localized in axons,
and has six isoforms produced from a single gene through alternative RNA splicing that are
identified by the number of binding domains [132]. Tau has received great attention because
mounting evidence indicates that hyperphosphorylation of Tau is the origin of Alzheimer's
disease [133]. Tau proteins interact with tubulins to promote their assembly into
microtubules, which in turn are stabilized by two manners, due to isoform-specific binding
to the filament and by serine/threonine kinase phosphorylations. It is thought to be an
inherently unfolded protein that undergoes aggregation by hyperphosphorylation, followed
by folding and protein cleavage [134, 135]. These posttranslational modifications can impact
the interaction of Tau with microtubules and thus, there may be specific isoforms of Tau that
are preferred chaperone substrates relative to others. Importantly, Tau is a client protein of
Hsp90 complexes. FKBP51 and FKBP52 are also co-chaperones of Hsp90•Tau complexes
[136, 137], as well as the IMM-like Ser/Thr phosphatase PP5. Fig. 3A shows a comparative
scheme of the common and highly homologous domains of these three IMMs close-related
to the Tau•microtubule architecture.
The peptidylprolyl-cis/trans-isomerase activity of those IMMs catalyzes phosphorylation-
dependent rotation in pSer/Thr-Pro peptide bond. The proline switch in the Tau
conformation triggers the PP5-dependent dephosphorylation of Ser/Thr residues
phosphorylated by two well-known Tau kinases, Cdk5 and GSK-3b [138–140] (Fig. 3B).
Subsequently, the PP5 dephosphorylated Tau protein can be shuttled back to the
microtubules. It seems that high-affinity binding of abnormal Tau to Hsp90 complexes may
have some counteracting effect on the aggregation process, since Hsp90 inhibitors can
ameliorate the aggregation process in several neurodegenerative diseases [141]. Initially,
Hsp40, Hsp70 and Hsp90 form a complex with mutated or distinctively phosphorylated Tau
species and subsequently recruit PP5 to facilitate dephosphorylation and refolding process.
When this is undermined, the complex engages the CHIP-dependent pathway, which poly-
ubiquitinates the Tau protein and triggers proteasomal degradation (Fig.3B).
It has recently been reported that other chaperone proteins, including Hsp27, Hsp70 and
CHIP (carboxy-terminus of Hsc70-interacting protein), can recognize abnormal Tau and
reduce its concentration by facilitating its dephosphorylation and degradation. Hsp27
preferentially binds to hyperphosphorylated Tau as well as paired helical filamentous Tau,
but not to non-phosphorylated Tau [142]. The expression of another sHsp, alphaB-crystallin
has been found in glial inclusions of tauopathies [143]. While Hsp27 also increases Tau
phosphorylation at Ser262, alphaB-crystallin decreases phosphorylated Tau and GSK-3β
levels [144]. Interestingly, Hsp27 is cross-linked with Tau in neurofilaments from
Alzheimer’s disease brains, and positive correlations have been found in the soluble protein
levels from of these brain tissues between Tau and molecular Hsp27, Hsp40, Hsp90,
alphaB-crystallin and CHIP [145]. Conversely, the levels of heat-shock proteins were
inversely correlated with the levels of granulated Tau oligomers, an intermediate of Tau
filaments. In a separate study, increased levels of Hsp70 and Hsp90 were found to promote
Tau solubility and microtubule binding in various cellular models [146]. Subsequent studies
show that Tau binds directly to Hsp70, and Bag1 has a role in this interaction [147]. Taken
together, these findings suggest that chaperones are necessary to maintain Tau in a non-
aggregated state, a consequence that may ultimately be deleterious for the brain. A novel
mechanism demonstrating that there are two pathways that can lead to opposing outcomes
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for Tau biology with regard to Hsp90; some chaperones preserve Tau whereas others
promote its degradation [148]. Furthermore, mutant Tau and not wild-type Tau, is
maintained by Hsp90 in tauopathies, and the inhibition of Hsp90 leads to reductions in the
pathogenicity of these mutant species [141].
4. Role of immunophilins in the organization of cytoskeleton
4.1. FKBP51 and FKBP52
FKBP52 was first described associated to microtubules in 1995 [73, 149] by confocal
microscopy studies and biochemical methods. The IMM was present in the subcellular
fractions containing either soluble proteins released from cells exposed to NP40 detergent,
or proteins released from the cytoskeleton exposed to calcium ions (i.e. in microtubule-
depolymerizing conditions). Exposure of cells to FK506 and rapamycin did not modify
significantly the colocalization with microtubules, indicating that the PPIase activity is not
required for such interaction. During mitosis, FKBP52 segregates from the region of the
chromosomes being mainly localized with the mitotic apparatus (centrosome, spindle and
interzone separating the chromosomes) [73]. Then, it was shown that this IMM associates to
dynein motors [59, 150], and more recently, it was postulated that FKBP52 can prevent
tubulin polymerization [71].
A high percentage of prolines are common to most intrinsically disordered proteins, and Tau
is no exception [151]. Nearly 10% of full-length Tau is composed of proline residues and
more than 20% of the residues between I151 and Q244 are proline. Most of the known
functions of Tau are mediated through microtubule binding domains distal to this proline-
rich region. As mentioned above, recent studies have revealed that both IMMs, FKBP51 and
FKBP52, interact directly with Tau protein [136, 137]. It has also been shown that Tau
phosphorylation increases its binding affinity for FKBP52, whereas the overexpression of
the IMM could prevent the accumulation of Tau protein induced by nerve growth factor.
While FKBP52 appears to inhibit tubulin polymerization, which is triggered by Tau protein
in vitro [136], FKBP51 stabilizes microtubules in a PPIase activity-dependent manner and
also enhances the association of Tau with Hsp90, although the FKBP51/Tau interaction is
not entirely dependent on the chaperone [137]. In this complex, phosphorylated Tau is in a
trans configuration, and the PPIase activity of FKBP51 isomerizes Tau to a cis
configuration, which enhances dephosphorylation of Tau by the IMM-like phosphatase PP5.
This is a critical event because dephosphorylated Tau is recycled to microtubules and
stabilizes them. On the other hand, highly phosphorylated Tau exhibits reduced microtubule
binding, leading to a loss of microtubule integrity.
Because both FKBP51 and FKBP52 possess PPIase activity and are capable to bind
phosphorylated Tau (Fig.3), it is currently unclear why FKBP51 is selectively able to
isomerize Tau and promote microtubule polymerization. One possible explanation could be
the fact that both TPR-domain IMMs, as well as CyP40 and PP5, compete for a common
Hsp90 binding-site in steroid receptor complexes [60, 150], so it would be possible that a
similar competition may take place in the phospho-Tau•Hsp90 heterocomplex containing a
TPR-domain cochaperone. In turn, the qualitative composition of such heterocomplex may
depend on the relative abundance of TPR proteins in a given cell, just like it has been
postulated for steroid receptors [60, 152, 153]. Moreover, structural comparison of FKBP51
and FKBP52 revealed that the TPR domains have different spatial orientations [70].
4.2. Roles of FKBPs on the cytoskeleton structure during the early neuronal differentiation
The fact that FKBP51 and FKBP52 affects neurite length may explain, at least in part, the
observations that the IMM ligand FK506 exhibits potent neurotrophic effects [74]. FK506
has been shown to promote neuroprotective and neuroregenerative effects in a number of
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injury models. The persistence of the capability to hasten nerve outgrowth by FK506-
derivatives devoid of immunosuppressive effects indicated that both effects are independent
[154], and experiments with mice where the FKBP1A gene was knocked-out clearly showed
that such neurotrophic effect is not mediated by FK506•FKBP12 complexes [155].
Recently, it was demonstrated that the FKBP52•Hsp90•p23 complex forms a perinuclear
structure in undifferentiated N2a neuroblastoma cells and hippocampal cells isolated from
rat embryos [74]. This peculiar perinuclear structure undergoes a rapid subcellular
redistribution along the cytoplasm (Fig.4A), which is detectable within the first hour of
stimulation with FK506. Importantly, FKBP52 is concentrated in terminal axons and
arborization areas. In agreement with the potential relevance of this IMM, knock-down
experiments showed that FKBP52 plays a key role in the architecture of these nuclear rings
since these structures faded in most cells (if not all of them) where the expression of the
IMM was abrogated. Importantly, both the rate of cell differentiation and neurite outgrowth
were also inhibited. Therefore, there is a direct relationship between the disassembly of the
chaperone complex and the progression of neuronal differentiation. The chaperones migrate
to the cytoplasm and become associated with cytoskeletal structures, whereas the nuclear
areas originally occupied by them in undifferentiated cells become transcriptionally active
after chaperones redistribute.
In contrast to FKBP52, FKBP51 is not induced during differentiation, remains in the cell
body and replaces FKBP52 in the annular structures of the nucleus complexed with Hsp70
[74]. While the overexpression of FKBP52 induces fast differentiation of N2a
neuroblastoma cells and neurites are longer, the expected opposite action is observed after
knocking-down FKBP52. On the other hand, FKBP51 overexpression decreases both the
neurite length and the rate of cell differentiation, whereas its knock-down favors neurite
outgrowth. In other words, it appears that both IMMs have antagonistic action during the
very early steps of neuronal differentiation.
Surprisingly, microtubules of undifferentiated neurons show a diffuse cytoplasmic
distribution, whereas they are arranged in the expected filamentary pattern after stimulation
with FK506 (Fig.4B). Simultaneously, the Hsp90 cochaperone p23 becomes associated to
neurofilaments (Fig.4C) and seems to be dissociated from both Hsp90 and FKBP52.
Importantly, after 5–6 days in culture with FK506 and no other trophic factor added to the
medium, embryonic day 17 rat hippocampal neurons show a new redistribution of FKBP52
only, such that the IMM is concentrated back in nuclei but, in contrast to what it was
observed in the undifferentiated state, FKBP52 distributes in the nucleus a diffuse manner
and shows no particular arrangement. All these observations suggest an active role of the
IMM•Hsp90•p23 complex in the arrangement of the neuronal cytoskeleton during the early
steps of cell differentiation. The above-described observations by Quinta et al. [103]
apparently collide with those reported by Chambroud [71, 136] in that these studies reported
that overexpression of FKBP52 reduced neurite outgrowth in response to 5 days in culture
with nerve growth factor in PC12 pheochromocytoma cells always maintained in a medium
with fetal serum. Therefore, there are important experimental differences between both
studies with respect to the cell type, length of stimulation in culture, and culture conditions
that justify those differences.
S100A proteins constitute a large family of calcium binding proteins which are linked to
many neurological disorders, inflammatory diseases, innate immunity, wound healing, and
cancer processes [156]. Several S100A proteins can bind to the TPR domain of FKBP52
protein, which leads to the dissociation of the Hsp90•FKBP52 complex in the presence of
calcium [157]. Apart from the possible crosstalk between S100A proteins and pro- or anti-
angiogenic factors, S100A4 and A13 have been reported to participate directly in the
angiogenic process in other tissues. Because the common denominator able to affect the
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biological activity of S100A proteins in all these biological processes is calcium
homeostasis, it could be implied that the function of FKBP52 can be regulated by calcium
within the cell, just like Tau phosphorylation and pathology in Alzheimer disease are
regulated. Moreover, FKBP52 counts with a calmodulin binding domain, whose biological
function is still enigmatic. Recently, FKBP52-dependent regulation of TRPC calcium
channels was reported in neurons [158].
4.3. The immunophilin-like protein-phosphatase PP5
The IMM-like protein phosphatase 5, PP5, has three TPR units for binding to the Hsp90
chaperone, a PPIase-like domain, and the Ser/Thr phosphatase sequence [159] (Fig. 3A).
PP5 can bind to trafficking glucocorticoid receptor heterocomplexes, is associated to
microtubules and interacts with dynein motors [66, 160–162]. The binding to Hsp90
complex activates the PP5 enzyme which is inactive outside the complex. As it was
discussed before, PP5 dephosphorylates Tau protein, and this dephosphorylation is
connected to the aggregates formed in Alzheimer disease [163]. The role of this
microtubule-associated IMM in the protection against Tau pathology is largely unknown,
although it is inferred that PP5, which is highly expressed in mammalian brain, possesses a
great potential to dephosphorylate Tau protein e.g. in Hsp90-FKBP51 complexes and
enhance the binding of Tau to microtubules.
5. Post-translational modifications
In addition to chaperone-assisted folding and assembly, covalent modification is often an
integral part of the biogenesis pathway leading to functional proteins. These post-
translational modifications affect folding or they can act as reversible switches able to
regulate the features of cytoskeletal proteins. In the case of actin, there is little or no
evidence in this regard, whereas tubulin is subject to a number of reversible modifications
that includes detyrosination, glutamylation/glycylation and acetylation [164]. Detyrosination
involves the removal of the gene-encoded C-terminal tyrosine of α-tubulin in microtubule
polymers by a still unidentified carboxypeptidase, this detyrosination being important for
kinesin-1 preferential binding to microtubules [165] and the consequent transport of
vimentin filaments [166]. On the other hand, glutamylation/glycylation involve the addition
of glutamate or glycine residues onto glutamate residues in the C-terminal tails of both α-
and β-tubulin [167]. While glycylation is mainly limited to tubulin incorporated into
axonemes (cilia and flagella), glutamylation is more prevalent in neuronal cells, centrioles,
and the mitotic spindle. Both modifications have been found on the same tubulin C-terminal
end and it has been proposed that there are cross-talks between the α- and β-tubulin tails that
regulate the type and extent for each post-translational modification [168].
It is accepted that most tubulin modifications occur on polymerized microtubules, whereas
the substrate for the reversal of these modifications is the free tubulin heterodimer [169].
Nonetheless, this heuristic model still deserves more conclusive experimental support. Some
of the tubulin-modifying enzymes might compete or cooperate with other factors involved in
regulating microtubule function. Thus, the class II histone-deacetylase HDAC6, known to
function as a potent α-tubulin deacetylase, binds to several microtubule-binding proteins
such as plus-end marker proteins [170]. Recent evidence suggests that tubulin acetylation is
involved in neurodegenerative diseases [171]. The list of HDAC6 partners with which the
enzyme can interact has expanded considerably during last several years. Unquestionably,
the regulation of HDAC6 activity by Hsp90 is one of the most striking [172, 173], the
chaperone itself being substrate of the enzyme. When HDAC6 was knocked-down, Hsp90
was hyperacetylated and much less of the Hsp90 cochaperone p23 was recovered associated
to Hsp90. The glucocorticoid receptor becomes defective in ligand binding, nuclear
translocation, and gene activation. The acetylated Hsp90 has a lower affinity for ATP than
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the wild-type Hsp90, and the dynamic the glucocorticoid receptor•Hsp90 heterocomplex
assembly/disassembly that occurs in HDAC6 knockdown cells is manifest as a ~100-fold
shift to the right versus wild-type cells in the dose response of steroid for transcriptional
activation. However, the receptor itself is not affected by HDAC6 [173].
Several other targets besides tubulin and Hsp90 were shown to be deacetylated by HDAC6.
Among them, cortactin, an actin-binding protein promoting Arp2/3-dependent actin
nucleation [174], whereas Hsp90 can regulate actin polymerization by interacting with and
enhancing the function of the Neural Wiskott-Aldrich syndrome protein, N-WASP [175].
Involvement of Hsp90 in HDAC6-dependent actin remodeling was also recently reported
[176]. Because assembly of tubulin is affected by Hsp90, both targets of HDAC6, cortactin
and Hsp90, could mediate the effect of HDAC6 inhibition on microtubules acting, directly
or indirectly, via remodeling of the actin cytoskeleton. The putative participation of Hsp90
or cortactin in the effect of HDAC6 inhibition on microtubule dynamics requires the
physical presence of HDAC6, rather than just increased acetylation of Hsp90 or cortactin,
since HDAC6 knockdown, which enhances such acetylation, is not sufficient for alteration
of microtubule dynamics.
6. Envoy
Clearly, molecular chaperones and immunophilins perform different but cooperating roles in
the regulation of cytoskeleton function. To date, many questions concerning the interplay of
these proteins and the cytoskeleton still remains to be fully elucidated. Clarification of these
issues requires a better understanding of our knowledge for all groups of proteins, molecular
chaperones, immunophilins, and cytoskeletal elements. Nevertheless, this is not an easy
issue. Within cells, the protein synthesis and their subsequent folding take place at the
ribosome surface. Both processes are rapid and occur in a protein-rich milieu that exerts
different influences on the final product. As a case in point, it is not always possible to
differentiate in vivo the individual effects of molecular chaperones that act cooperatively
and/or sequentially on nascent proteins, so the problem was partially overcome by analysis
of cells with mutated chaperones. Even though this approach has provided many answers, it
is only limited to those organisms for which genetic manipulation is possible. On the other
hand, while studies in vitro allow defined conditions, they suffer from the obvious
limitations imposed by the artificial environment. Protein concentration and diversity in
vitro are often much lower than in the cytoplasm and only one of many cooperative
reactions influencing protein folding may be under study. Thus, a molecular chaperone
might seem unrelated to a particular cytoskeletal component only because, for example, a
cochaperone is missing or not properly activated. Conversely, molecular chaperones tend to
recognize hydrophobic regions exposed to the aqueous environment, a generalized
mechanism providing ample opportunity for non-specific interactions. This concern is
especially pertinent in an in vitro situation, where relatively high levels of a limited number
of proteins dissolved in low salt non-physiological buffers may drive inappropriate
reactions. Artifactual protein-protein associations are also encountered when searching cells
for microtubule-associated proteins, an example which provides a strong cautionary message
to the study of chaperone-substrate interactions. In spite of all these problems associated
with their study, the available evidence proves univocally that all types of molecular
chaperones not only assist the formation of cytoskeletal proteins, but also influence the
structural and functional organization of microtubules, microfilaments and intermediate
filaments. This has considerable consequences in the progression of the cell cycle, cell
death, cellular adaptive response to stress, cell differentiation, neuroprotection,
neuroregeneration, progression and aggressiveness of different tumor phenotypes, etc.
Therefore, research into virtual drug design and protein configuration determination is
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gaining progressive attention since drug development in both fields, biology and medicine,
recognizes now the potential for multipoint interventions.
Highlights
Cytoskeletal structure is continually remodeled to accommodate normal cell growth and
to respond to pathophysiological cues. As a consequence, several cytoskeleton-
interacting proteins become involved in a variety of cellular processes such as cell
growth and division, cell movement, vesicle transportation, cellular organelle location
and function, localization and distribution of membrane receptors, and cell-cell
communication. Molecular chaperones and immunophilins are counted among the most
important proteins that interact closely with the cytoskeleton network, in particular with
microtubules and microtubule-associated factors. In several situations, heat-shock
proteins and immunophilins work together as a functionally active heterocomplex,
although both types of proteins also show independent actions. In circumstances where
homeostasis is affected by environmental stresses or due to genetic alterations, chaperone
proteins help to stabilize the system. Molecular chaperones facilitate the assembly,
disassembly and/or folding/refolding of cytoskeletal proteins, so they prevent aberrant
protein aggregation. Nonetheless, the roles of heat-shock proteins and immunophilins are
not limited to solve abnormal situations, but they also have an active participation during
the normal differentiation process of the cell and are key factors for many structural and
functional rearrangements during this course of action. Cytoskeleton modifications
leading to altered localization of nuclear factors may result in loss- or gain-of-function of
such factors, which affects the cell cycle and cell development. Therefore, cytoskeletal
components are attractive therapeutic targets, particularly microtubules, to prevent
pathological situations such as rapidly dividing tumour cells or to favor the process of
cell differentiation in other cases. In this review we will address some classical and novel
aspects of key regulatory functions of heat-shock proteins and immunophilins as
housekeeping factors of the cytoskeletal network.
Abbreviations
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Figure 1. Model of the ATP cycle of Hsp90 and its interaction with Hop, IMMs and p23
The reversible exchange of ADP by ATP induces a conformational change in Hsp90 dimers
that locks ATP into its binding site. This conformation state is stablized by the cochaperone
p23, and Hsp90 recruits TPR-domain immunophilins (IMMs) and shows optimal
chaperoning properties to interact with client proteins. Hsp90 returns to the ADP-bound
conformation due to its intrinsic ATPase activity. Molybdate traps Hsp90 in its active
conformation because the γ-phosphate is replaced by the oxyanion and prevent ADP
dissociation (generating and ATP-like state). On the other hand, the benzoquinone
ansamycin antibiotic geldanamycin (GA) stabilizes the ADP-bound state of Hsp90 favoring
its interaction with the TPR-domain cochaperone Hop rather than with IMMs.
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Figure 2. Cytoskeleton proteostasis is managed by molecular chaperones
Proteins emerging from ribosomes can be delivered to the CCT/TRiC chaperone machinery
for correct folding. Those proteins that cannot be shaped properly are targeted to
degradation. Based on their abundance, actin and tubulin probably occupy a substantial
proportion of CCT/TRiC complexes at any given time. Native actin and tubulin assemble
into microfilaments and microtubules in a nucleotide-regulated manner (ADP/ATP and
GDP/GTP, respectively) with the additional assistance of other factors (not depicted here for
simplicity), whereas free monomers o dimers can be targeted to proteasome degradation.
Oligomeryzed small heat-shock proteins (sHsp)n such as Hsp25/Hsp27 can be
phosphorylated (asterisks) and form tetrameric structures (Phospho-sHsp)4 able to stabilize
filaments, in particular when the cells are exposed to stress. In turn, the soluble Hsp90-based
heterocomplex matures in the cytosol (top of the figure) by assembling Hsp90 with Hsp70,
Hsp40, p23 and a TPR-domain protein (TPR1) that may represent the need of Hop for
priming the complex. This original heterocomplex may undergo further modifications by
exchanging the TPR-domain protein, for example, Hop (represented by TPR1 in the scheme)
is replaced by a high molecular weight IMM (TPR2). The ‘mature’ heterocomplex stabilizes
and also provides gain-of-function properties to several client proteins that may remain
soluble or can interact with the cytoskeleton network. It should be pointed out that even the
proteasome are ribosomes are also assisted by a complex of chaperones (not depicted).
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Figure 3. Regulation of the Tau-microtubule interaction
(A) Schematic representation of the structural domains of the high molecular weight
immunophilins FKBP51, FKBP52 and PP5 involved in Tau regulation. TPR,
tetratricopeptide repeat domain or Hsp90-interacting domain; FK506, macrolide binding site
to the PPIase-1 domain; HD, hinge domain (reach in polar amino acids complementary to
the nuclear localization signal 1 of steroid receptors); NTP, nucleotide binding domain;
CMD, calmodulin binding domain; ID, inhibitory domain. (B) Tau is phosphorylated
(asterisks) in Ser and Thr residues by GSK-3b or CDK5 generating a number phospho-
isoforms. Accumulation of misfolded phospho-Tau (toxic) generates aggregates as a
protective response, an event that requires Hsp90 and Hsp70 and is counteracted by
overexpression of FKBP52 and the Hsp90 inhibitor geldanamycin. The chaperone
heterocomplex can refold Tau, whose dephosphorylated isoforms are reincorporated to
microtubules. The IMM-like Ser/Thr-protein phosphatase PP5 plays a key role in this regard
and is assisted by FKBP51, an IMM that enhances Tau dephosphorylation and its recycling
in a PPIase-dependent manner [137]. Therefore, deficiencies in the isomerase activity of
FKBP51 or in the dephosphorylation step can cause the accumulation of phosphorylated Tau
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protein followed by aggregation. The TPR-domain protein CHIP (C terminus of Hsc70-
interacting protein) favors Tau polyubiquitination and its proteasomal degradation.
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Figure 4. Subcellular redistribution of chaperones and cytoskeleton rearrangement during
neuronal differentiation
(A) Images by confocal microscopy of embryonic hippocampal neurons prior and 24 h after
treatment with 1 µM FK506. Image on the right hand shows a wider field. (B) Microtubules
reorganize after 3 h of differentiation. (C) Intermediate filaments (IF) of FK506-
differentiated neurons recruit the Hsp90-cochaperone p23.
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